Skip to main content
. 2011 Nov 20;20(3):647–652. doi: 10.1007/s00520-011-1306-6

Fig. 1.

Fig. 1

Dose delays of >3 days in patients who received at least two chemotherapy cycles, dose reductions of ≥10% in cyclophosphamide or doxorubicin in any cycle, and patients achieving RDI ≥90%. For dose delays, superscript a, N = 80; superscript b, N = 325; superscript c, N = 128; superscript d, N = 563